Lonza, BioNTech, Evotec, Zealand Pharma, Oncopeptides
Lonza: higher profitability targets at its Capital Markets Day; BioNTech: BNT113 misses on progression-free survival, trial continues for overall survival; Evotec: nine-month figures above expectations, guidance confirmed; Zealand Pharma: AI protein deal with Generate Biomedicines; Oncopeptides: SEK 100M share issue for its glioblastoma programme.
Lonza, BioNTech, Evotec, Zealand Pharma, Oncopeptides Read Post »